Therefore, neo-adjuvant and/or adjuvant application of anti-PD-1/-PD-L1 therapy may be beneficial in patients with a high risk of postoperative MCC recurrence [47]. This evidence concerns the gene PDCD1 and Merkel cell skin cancer.